# ScoreItem: Ecodopplercardiograma - FEVE Homens

**ID:** `019bf31d-2ef0-72e8-93dc-40f139652223`
**FullName:** Ecodopplercardiograma - FEVE Homens (Exames - Imagem)
**Unit:** %
**Gender:** male

**Preparation Metadata:**
- Quality Grade: **GOOD**
- Total Chunks: 30 de 7 artigos
- Avg Similarity: 0.546

---

## Contexto

Voc√™ √© um especialista em medicina funcional integrativa e est√° contribuindo com o **Escore Plenya** ‚Äî um escore completo de an√°lise de sa√∫de que avalia todos os aspectos da sa√∫de, performance e longevidade humana. Cada ScoreItem representa um par√¢metro cl√≠nico, laboratorial, gen√©tico, comportamental ou hist√≥rico que comp√µe esse escore.

Seu papel √© gerar conte√∫do cl√≠nico de alta qualidade para enriquecer cada par√¢metro do escore com relev√¢ncia cl√≠nica, orienta√ß√£o ao paciente e conduta pr√°tica.

**Regras inegoci√°veis:**
- Use **apenas** o conhecimento m√©dico real consolidado e os dados presentes nos chunks cient√≠ficos abaixo
- **N√£o alucine, n√£o invente** dados, estudos, estat√≠sticas ou refer√™ncias que n√£o estejam nos chunks ou no seu conhecimento m√©dico estabelecido
- Se um dado espec√≠fico n√£o constar nos chunks e n√£o for do seu conhecimento consolidado, **n√£o o inclua**
- Seja preciso: prefira omitir a inventar

## Instru√ß√£o

Com base nos chunks cient√≠ficos abaixo, gere as respostas em formato JSON.

**O JSON deve obrigatoriamente conter o campo `score_item_id` com o valor `019bf31d-2ef0-72e8-93dc-40f139652223`.**

```json
{
  "score_item_id": "019bf31d-2ef0-72e8-93dc-40f139652223",
  "clinical_relevance": "Texto t√©cnico para m√©dicos (1000-5000 chars): defini√ß√£o fisiol√≥gica precisa, valores de refer√™ncia e interpreta√ß√£o, fisiopatologia resumida, dados epidemiol√≥gicos com n√∫meros concretos, estratifica√ß√£o de risco baseada em evid√™ncias.",
  "points": 1,
  "patient_explanation": "Texto simples para pacientes (500-1000 chars): o que √© este par√¢metro sem jarg√µes, por que √© importante para a sa√∫de, o que valores alterados podem significar. Tom tranquilizador e educativo.",
  "conduct": "Conduta cl√≠nica em Markdown (1000-5000 chars): investiga√ß√£o complementar necess√°ria, crit√©rios de encaminhamento a especialistas, interven√ß√µes baseadas em evid√™ncias. Use bullet points, se√ß√µes e negrito."
}
```

**Regras para `points` (1-50):**
- Baixo impacto cl√≠nico: 1-9 pts
- Alto impacto cl√≠nico: 10-19 pts
- Alto impacto em mortalidade: 20-50 pts
- Crit√©rios: gravidade/mortalidade (40%), preval√™ncia (30%), intervencionabilidade (30%)

---

### Contexto Cient√≠fico

**ScoreItem:** Ecodopplercardiograma - FEVE Homens (Exames - Imagem)
**Unidade:** %
**G√™nero:** male

**30 chunks de 7 artigos (avg similarity: 0.546)**

### Chunk 1/30
**Article:** Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography (2015)
**Journal:** Journal of the American Society of Echocardiography
**Section:** abstract | **Similarity:** 0.628

Updated guidelines for echocardiographic assessment. Normal LVEF ‚â•54% in women by Simpson method. Sex-specific reference ranges are essential for accurate diagnosis of systolic dysfunction.

---

### Chunk 2/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.586

herauthorshavenothing
todisclose.References1.McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,B√∂hmM,etal.;ESCScienticDocumentGroup.2021ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailure:DevelopedbytheTaskForcefor
thediagnosisandtreatmentofacuteandchronicheartfailureoftheEuropean
SocietyofCardiology(ESC).WiththespecialcontributionoftheHeartFailure
Association(HFA)oftheESC.EurJHeartFail2022;24:4‚Äì131.https://doi.org/10.1002/ejhf.23332.Guidelinesforthediagnosisofheartfailure.TheTaskForceonHeartFailureoftheEuropeanSocietyofCardiology.EurHeartJ1995;16:741‚Äì751.3.HeidenreichPA,BozkurtB,AguilarD,AllenLA,ByunJJ,ColvinMM,etal.AHA/ACC/HFSAGuidelineforthemanagementofheartfailure:Executive
summary:AreportoftheAmericanCollegeofCardiology/AmericanHeart
AssociationJointCommitteeonClinicalPracticeGuidelines.JAmCollCardiol2022;79:1757‚Äì1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-L√≥pezE,BarallatJ,Cserk√≥ov√°A,G√°lvez-Mont√≥nC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsid

---

### Chunk 3/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.580

(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31%)0.98III23(24.46%)7(23.33%)16(25.00%)0.87
IV5(5.33%)2(6.67%)3(4.69%)0.65Aetiology(ischaemic)27(28.7%)17(56.7%)10(15.6%)0.01Yearofdisease5[2‚Äì10.75]4[1‚Äì9.75]7[2.75‚Äì12]0.1AF11(22.4%)4(13.33%)7(10.90%)0.73
Beta-blockers66(91.7%)24(72.00%)42(65.60%)0.15
ACE-I31(43.1%)12(40.00%)19(29.70%)0.22ARBs26(36.1%)9(30.00%)17(26.60%)0.72MRA26(36.1%)8(26.70%)18(28.12%)0.88
ICD26(36.6%)8(26.66%)18(28.10%)0.88
CRT10(14.1%)1(3.33%)9(14.10%)0.15IGF-1D50(53.2%)16(53.3%)34(53.1%)0.98DHEA-SD73(77.7%)29(97.7%)44(68.7%)0.01
TypeIIdiabetes26(27.7%)6(20%)20(31.2)0.37Abbreviations:TD,testosteronedeciency;NTproBNP,N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmit

---

### Chunk 4/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.575

fortheman-
agementofheartfailure:Areportof
theAmericanCollegeofCardiologyFoundation/AmericanHeartAssociationtaskforceonpracticeguidelines.JAmCollCardiol.2013;62:e147‚Äìe239.3.BealeAL,MeyerP,MarwickTH,LamCSP,KayeDM.Sexdifferencesincardio-vascularpathophysiology:Whywomen
areoverrepresentedinheartfailurewith
preservedejectionfraction.Circulation.2018;138:198‚Äì205.4.ShahKS,XuH,MatsouakaRA,BhattDL,HeidenreichPA,HernandezAF,Devore
AD,YancyCW,FonarowGC.Heartfail-urewithpreserved,borderline,andre-ducedejectionfraction:5-yearout-
comes.JAmCollCardiol.2017;70:2476‚Äì2486.5.HsichEM,Grau-SepulvedaMV,HernandezAF,PetersonED,Schwamm
LH,BhattDL,FonarowGC.Sex
differencesinin-hospitalmortalityinacutedecompensatedheartfailurewithreducedandpreservedejection
fraction.AmHeartJ.2012;163:430‚Äì437.e3.6.CittadiniA,SalzanoA,IacovielloM,TriggianiV,RengoG,CacciatoreF,
MaielloC,LimongelliG,MasaroneD,
PerticoneF,CimellaroA,PerroneFilardiP,PaolilloS,ManciniA,VolterraniM,VrizO,CastelloR,PassantinoA,Campo
M,ModestiPA

---

### Chunk 5/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.572

rmed
instudiesinvolvinghumanparticipantswereinaccordancewiththeethicalstandardsoftheinstitutionaland/orna-tionalresearchcommitteeandwiththe1964Declaration
ofHelsinkianditslateramendmentsorcomparableethicalstandards.Medicalhistory,medicationuse,andclinicaldatawerere-cordedatthetimeoftheenrolmentasalreadydescribed.6,11Briey,patientsunderwentechocardiography(includingtwo-dimensional,Doppler,Color,andtissueDoppleranalysis)and
symptom-limitedexercisetestandmaximaloxygenuptake(VO2max)wasmeasuredbyabreath-to-breathrespiratorygasanalysis.Bloodsampleswerecollectedbyvenipuncture
afterovernightfast.Toobtainserumandplasma,sampleswerecentrifugedwithin30min,frozen,andstoredat80¬∞Cuntilassayed.SerumN-terminalprohormonebrainnatriureticpeptide(NT-proBNP)concentrationsweremea-suredbyanelectrochemiluminescenceimmunoassay(ECLIAbyRochediagnostics)usingaRocheElecsysanalyser.Serumhormoneswereanalysedinacentralizedcore-lab(IRCCSSDN,Naples,Italy).Insulinandinsulingrowth
2A.M.Marraetal.ESCHeartFailure(2022)DO

---

### Chunk 6/30
**Article:** Sex-Specific Reference Values for Left Ventricular Ejection Fraction in Heart Failure: The MAGGIC Meta-Analysis (2013)
**Journal:** Circulation
**Section:** abstract | **Similarity:** 0.567

Women with heart failure have higher LVEF than men. Sex-specific cutoffs improve HFpEF vs HFrEF classification. Women have better outcomes at equivalent LVEF values compared to men.

---

### Chunk 7/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.562

calPracticeGuidelines.JAmCollCardiol2022;79:1757‚Äì1780.https://doi.org/10.1016/j.jacc.2021.12.0114.Revuelta-L√≥pezE,BarallatJ,Cserk√≥ov√°A,G√°lvez-Mont√≥nC,JaffeAS,JanuzziJL,etal.Pre-analyticalconsiderationsinbiomarkerresearch:Focusoncardiovasculardisease.ClinChemLabMed.2021;59:1747‚Äì1760.5.Pop-BusuiR,JanuzziJL,BruemmerD,ButaliaS,GreenJB,HortonWB,etal.Heartfailure:Anunderappreciatedcomplicationofdiabetes.Aconsensusreportofthe
AmericanDiabetesAssociation.DiabetesCare2022;45:1670‚Äì1690.https://doi.org/10.2337/dci22-00146.BozkurtB,CoatsAJS,TsutsuiH,AbdelhamidCM,AdamopoulosS,AlbertN,etal.Universaldenitionandclassicationofheartfailure:AreportoftheHeartFailureSocietyofAmerica,HeartFailureAssociationoftheEuropean
SocietyofCardiology,JapaneseHeartFailureSocietyandWritingCommittee
oftheUniversalDenitionofHeartFailure:EndorsedbytheCanadianHeart
FailureSociety,HeartFailureAssociationofIndia,CardiacSocietyofAustralia
andNewZealand,andChineseHeartFailureAssociation.EurJHeartFail2021;23:352‚Äì

---

### Chunk 8/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.558

N-terminalproB-typenatriureticpeptide;BSA,bodysurfacearea;SBP,systolicbloodpressure;DBP,diastolicbloodpressure;eGFR,estimatedglomelurarltrationrate;LAVi,leftatrialvolumeindex;e,earlydiastolictransmitralowvelocity;E‚Ä≤,earlydiastolicmitralannularvelocity;TAPSE,tricuspidannularplaneexcursion;PASP,pulmonaryarterialsystolicpressure;RVOT-AT,rightventricularoutowtractaccelerationtime;VO2peak,peakoxygenconsumption;NYHA,NewYorkHeartAssociation;AF,atrialbrillation;ACE-I,angiotensin-converting-enzymeinhibitors;ARBs,angiotensin-receptorblockers;MRA,mineralocorticoid-receptorantagonist;ICD,implantablecardioverter-debrillator;CRT,cardiacresynchronizationtherapy;IGF-1D,IGF-1deciency;DHEA-SD,DHEA-Sdeciency.

---

### Chunk 9/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.551

ducesbetterorworseresultsthanaerobictraining
alone(Haykowskyetal.,2007).Basedontheabove,thefollowingisrecom-mended:ÔøΩTrainingisrecommendedforallheartfailurepatientsinNYHAfunctionclassII‚ÄìIIIonafullytitratedmedicationregimenandwellcompensatedfor3weeks.ÔøΩAllpatientsshouldbeassessedbyacardiologist
beforeembarkingonatrainingprogram.ÔøΩForthesakeofcautionandinordertodetermine
individualexercisecapacity,thetrainingshouldbe
precededbyasymptom-limitedexercisetest.31Exerciseasmedicine‚Äìevidenceforprescribingexercise
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

ÔøΩAsupervised,tailoredtrainingprogramisrecom-mendedafteraninitialexercisetest:Trainingprogramsforheartfailurepatientswithverylowexercisecapacitymustbestructuredwithshortdailysessionsoflow-intensityexercise,gradu-
allyincreasingdurationastheprogramprogresses.

---

### Chunk 10/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.548

patientswithheartfailure.AdeÔ¨Ånite
impactonheartfailure-relatedhospitalization,phys-
icalfunctionandqualityoflifehasbeenidentiÔ¨Åed.

---

### Chunk 11/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.547

meta-analysis.LancetDiabetesEndocrinol20164(10):840‚Äì849.https://doi.org/10.1016/S2213-8587(16)30196-649.SciricaBM,BraunwaldE,RazI,CavenderMA,MorrowDA,JarolimP,etal.SAVOR-TIMI53SteeringCommitteeandInvestigators*.Heartfail-ure,saxagliptin,anddiabetesmellitus:ObservationsfromtheSAVOR-TIMI
53randomizedtrial.Circulation2014;130:1579‚Äì1588.https://doi.org/10.1161/CIRCULATIONAHA.114.010389...............50.MagnussonM,MelanderO,IsraelssonB,GrubbA,GroopL,JovingeS.ElevatedplasmalevelsofNt-proBNPinpatientswithtype2diabeteswithoutovert
cardiovasculardisease.DiabetesCare2004;27:1929‚Äì1935.https://doi.org/10.2337/diacare.27.8.192951.VermaS,SharmaA,KanumilliN,ButlerJ.Predictorsofheartfailuredevelopmentintype2diabetes:Apracticalapproach.CurrOpinCardiol2019;34:578‚Äì583.https://doi.org/10.1097/HCO.0000000000000647¬©2023EuropeanSocietyofCardiology.

---

### Chunk 12/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** introduction | **Similarity:** 0.547

nymedium,providedtheoriginalworkisproperlycited,theuseisnon-commercialandnomodicationsoradaptationsaremade.ESCHEARTFAILUREESCHeartFailure(2022)PublishedonlineinWileyOnlineLibrary(wileyonlinelibrary.com)DOI:10.1002/ehf2.14117
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

*Correspondenceto:AntonioCittadini,DepartmentofTranslationalMedicalSciences,Director,DivisionofInternalMedicine&Metabolism&Rehabilitation,UniversityFedericoII,80131Naples,Italy.Email:antonio.cittadini@unina.itAlbertoM.MarraandRobertaD‚ÄôAssanteequallycontributedtothework.Fundinginformation:TheworkwassupportedbyunrestrictedgrantfromMerckSeronoItaly.IntroductionDespiteimprovementsintherapyandmanagement,chronicheartfailure(CHF)isstilloneofthemajorhealthproblemswithanowadaysestimated5yearmortalityrateof50%.1Inthisregard,thereisanurgentneedofinnovativetherapeu-ticapproachespotentiallyabletohaltdiseaseprogressionandincreasesurvival.1Notwiths

---

### Chunk 13/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.542

congestiveheartfailureinanurgent-caresetting.JAmCollCardiol2001;37:379‚Äì385.https://doi.org/10.1016/s0735-1097(00)01156-619.CollinsSP,LindsellCJ,StorrowAB,AbrahamWT;ADHEREScienticAdvisoryCommittee,InvestigatorsandStudyGroup.Prevalenceofnegativechestradio-graphyresultsintheemergencydepartmentpatientwithdecompensatedheart
failure.AnnEmergMed2006;47:13‚Äì18.https://doi.org/10.1016/j.annemergmed.2005.04.00320.Bay√©s-Gen√≠sA,Santal√≥-BelM,Zapico-Mu√±izE,L√≥pezL,CotesC,BellidoJ,etal.N-terminalprobrainnatriureticpeptide(NT-proBNP)intheemergencydiagnosisandin-hospitalmonitoringofpatientswithdyspnoeaandventriculardysfunction.EurJHeartFail2004;6:301‚Äì308.https://doi.org/10.1016/j.ejheart.2003.12.01321.LamLL,CameronPA,SchneiderHG,AbramsonMJ,M√ºllerC,KrumH.Meta-analysis:EffectofB-typenatriureticpeptidetestingonclinicaloutcomes
inpatientswithacutedyspneaintheemergencysetting.AnnInternMed2010;153:728‚Äì735.https://doi.org/10.7326/0003-4819-153-11-201012070-0000622.MoeGW,HowlettJ,JanuzziJL,ZowallH

---

### Chunk 14/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.540

accausesofdyspnoea.ForrulinginheartfailureintheED,age-adjustedcut-pointshavebeenestablished:450pg/mlforpatientsunder50years,¬©2023EuropeanSocietyofCardiology.

---

### Chunk 15/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.540

¬±SDMean¬±SDMean¬±SDAge(years)66.18¬±10.2668.93¬±9.74564.89¬±10.3250.12NTproBNP(pg/ml)2597.05¬±4093.042794.47¬±3380.142504.52¬±4409.550.72
BSA(m2)1.70¬±0.161.68¬±0.11.71¬±0.190.34SBP(mmHg)123.29¬±17.82121.32¬±16.86124.24¬±18.370.53DBP(mmHg)75.46¬±12.3975.05¬±9.5175.65¬±13.650.85
eGFR(ml/min)68.61¬±34.2854.27¬±23.0275.55¬±36.760.001
Haemoglobin(g/dl)12.85¬±1.5312.50¬±1.2113.01¬±1.650.13Albumin(%)56.8¬±5.256.6¬±7.756.9¬±3.70.9Testosterone(ng/dl)48.80¬±61.8613.60¬±6.6362.55¬±68.16<0.001Ejectionfraction(%)33.81¬±6.4633.20¬±7.6634.10¬±5.850.53
LAVi(ml/m2)49.46¬±25.5755.51¬±30.2446.63¬±22.770.17e/E‚Ä≤14.68¬±9.9613.04¬±4.9512.53¬±6.400.16TAPSE(mm)18.82¬±4.5117.78¬±4.2619.31¬±4.560.12
PASP(mmHg)34.38¬±13.2537.69¬±13.7232.84¬±12.840.98
RVOT-AT(ms)103.27¬±36.47112.11¬±34.7497.15¬±37.730.35TAPSE/PASP(mm/mmHg)0.63¬±0.290.53¬±0.220.68¬±0.320.008Pericardialeffusion14(15.20%)7(23.30%)7(10.93%)0.11
VO2peak(ml*kg1*min1)(n=67)20.61¬±4.7018.89¬±4.9221.31¬±4.920.03NYHAclassII66(70.21%)21(70.00%)45(70.31

---

### Chunk 16/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.540

oninpri-marycare.EurHeartJ2010;31:1881‚Äì1889.https://doi.org/10.1093/eurheartj/ehq16346.ClelandJGF,PfefferMA,ClarkAL,JanuzziJL,McMurrayJJV,MuellerC,etal.Thestruggletowardsauniversaldenitionofheartfailure‚Äìhowtoproceed?EurHeartJ2021;42:2331‚Äì2343.https://doi.org/10.1093/eurheartj/ehab08247.TaylorCJ,Lay-FlurrieSL,Ord√≥√±ez-MenaJM,GoyderCR,JonesNR,RoalfeAK,etal.NatriureticpeptidelevelatheartfailurediagnosisandriskofhospitalisationanddeathinEngland2004-2018.Heart2022;108:543‚Äì549.https://doi.org/10.1136/heartjnl-2021-31919648.NatriureticPeptidesStudiesCollaboration;WilleitP,KaptogeS,WelshP,Butter-worthAS,ChowdhuryR,SpackmanSA,etal.,Natriureticpeptidesandintegratedriskassessmentforcardiovasculardisease:Anindividual-participant-data¬©2023EuropeanSocietyofCardiology.

1898A.Bayes-Genisetal.

---

### Chunk 17/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.537

alDenitionofHeartFailure:EndorsedbytheCanadianHeart
FailureSociety,HeartFailureAssociationofIndia,CardiacSocietyofAustralia
andNewZealand,andChineseHeartFailureAssociation.EurJHeartFail2021;23:352‚Äì380.https://doi.org/10.1002/ejhf.21157.ChioncelO,LainscakM,SeferovicPM,AnkerSD,Crespo-LeiroMG,HarjolaVP,etal.Epidemiologyandone-yearoutcomesinpatientswithchronicheartfailureandpreserved,mid-rangeandreducedejectionfraction:AnanalysisoftheESCHeartFailureLong-TermRegistry.EurJHeartFail2017;19:1574‚Äì1585.https://doi.org/10.1002/ejhf.8138.MukoyamaM,NakaoK,HosodaK,SugaS,SaitoY,OgawaY,etal.Brainnatriureticpeptideasanovelcardiachormoneinhumans.Evidenceforan
exquisitedualnatriureticpeptidesystem,atrialnatriureticpeptideandbrain
natriureticpeptide.JClinInvest1991;87:1402‚Äì1412.https://doi.org/10.1172/JCI1151469.PembertonCJ,JohnsonML,YandleTG,EspinerEA.Deconvolutionanalysisofcardiacnatriureticpeptidesduringacutevolumeoverload.Hypertension2000;36:355‚Äì359.https://doi.org/10.1161/01.hyp.36.3.35510.M

---

### Chunk 18/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.537

ingwithNT-proBNPenablesinterventionstodelayorpreventdiseaseprogressionandthedevelopmentofheartfailure.ThemnemonicFIND-HFisintroducedasareminderforearlydiag-nosisofheartfailureforbothhealthcareprofessionalsandpatients.¬©2023EuropeanSocietyofCardiology.

1896A.Bayes-Genisetal.

---

### Chunk 19/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.532

3‚Äì815.https://doi.org/10.1002/ejhf.147124.MuellerC,ScholerA,Laule-KilianK,MartinaB,SchindlerC,BuserP,etal.UseofB-typenatriureticpeptideintheevaluationandmanagementofacutedyspnea.NEnglJMed2004;350:647‚Äì654.https://doi.org/10.1056/NEJMoa03168125.SiebertU,MilevS,ZouD,LitkiewiczM,GagginHK,TirapelleL,etal.EconomicevaluationofanN-terminalproB-typenatriureticpeptide-supporteddiagnos-ticstrategyamongdyspneicpatientssuspectedofacuteheartfailureinthe
emergencydepartment.AmJCardiol2021;147:61‚Äì69.https://doi.org/10.1016/j.amjcard.2021.01.03626.MuellerC,Laule-KilianK,SchindlerC,KlimaT,FranaB,RodriguezD,etal.Cost-effectivenessofB-typenatriureticpeptidetestinginpatientswithacutedys-pnea.ArchInternMed2006;166:1081‚Äì1087.https://doi.org/10.1001/archinte.166.10.108127.JanuzziJL,vanKimmenadeR,LainchburyJ,Bayes-GenisA,Ordonez-LlanosJ,Santalo-BelM,etal.NT-proBNPtestingfordiagnosisandshort-termprognosisinacutedestabilizedheartfailure:Aninternationalpooledanalysisof1256patients:TheInternationalCollabor

---

### Chunk 20/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.531

sensus
documentalignwiththeNICEguidelinesonchronicheartfailure,
whichrecommendacut-offvalueofNT-proBNP>2000pg/ml.40InananalysisofprimarycaredatafromEngland,anNT-proBNPvalue
of>2000pg/mlwasassociatedwithamorethantwo-foldhigherriskofheartfailurehospitalizationand50%higherriskofmortalityascomparedwithanNT-proBNPof400‚Äì2000pg/ml.47Wesug-gestthat,irrespectiveofageandsex,patientswithanNT-proBNP
>2000pg/mlshouldbeprioritizedforechocardiographyandclini-calevaluationwithin2weeksofdiagnosis(Figure2).NT-proBNPinasymptomaticpatientswithriskfactors:heart
stressVariousriskfactors,suchashypertension,atheroscleroticcardio-vasculardisease,diabetes,obesity,andothers,contributetoanincreasedsusceptibilitytothedevelopmentofheartfailure.Intheabsenceofsymptomsofheartfailure,patientswithriskfactorsmay
exhibiteitherhearthealthorheartstress.Hearthealthrefersto
individualswhohaveastructurallynormalheartandnormalplasma
concentrationsofNPsandtroponins.¬©2023EuropeanSocietyofCardiology.

---

### Chunk 21/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** introduction | **Similarity:** 0.530

ontraindicationsThefollowingcontraindicationsareinagreementwithaEuropeanWorkingGroup(Gianuzzi&
Tavazzi2001).ÔøΩAcuteCHU(AMIorunstableangina),untilthe
conditionhasbeenstableforatleast5daysÔøΩDyspneaatrestÔøΩPericarditis,myocarditis,endocarditisÔøΩSymptomaticaorticstenosisÔøΩSeverehypertension.Thereisnoestablished,docu-
mentedborderlinebloodpressurevaluedeemedto
bethecut-offpointforincreasedrisk.Generallyit
isrecommendedthatdemandingphysicalexercise
beavoidedinthecaseofsystolicBP>180ordias-
tolicBP>105mmHgÔøΩFeverÔøΩSeriousnon-cardiacdiseaseHeartfailureBackgroundHeartfailureisaconditionwheretheheartisunabletopumpsufÔ¨ÅcientlytomaintainbloodÔ¨Çowtomeetthemetabolicneedsoftheperipheraltissue(Braun-
wald&Libby,2008).Heartfailureisaclinicalsyn-
dromewithsymptomssuchasÔ¨Çuidretention,
breathlessness,orexcessivetirednesswhenrestingor
exercising,andwithobjectivesymptomsofreduced
systolicfunctionoftheleftventricleatrest.Asymptomaticleftventriculardysfunctionisoftentheprecursorofthissyndrome.Sympt

---

### Chunk 22/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.530

%CI1.13‚Äì4.50;P=0.02forcardiovascularhospitalization)(TableS1).Similarresultswereobtainedafterexcluding(n=8)patientswithLVEFbetween40and45%(Table2).DiscussionThemainndingsofthecurrentstudyarethat(1)TDishighlyprevalentamongwomenwithHFrEF,around
one-third;(2)whenpresent,TDshapesaclustercharacter-izedbyreducedexercisecapacity,abnormalrightventricular-arterialcouplingandimpairedrenalfunction;(3)
TDhasasignicantimpactonmorbidityandmortalityoffemalepatientsaffectedbyHFrEFbeinganindependent
Testosteronedeciencyinwomenwithheartfailure3ESCHeartFailure(2022)DOI:10.1002/ehf2.14117
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

predictorofall-causemortalityandcardiovascularhospitali-zation.Tothebesttoourknowledge,thisreportistherstaddressingtheimpactofTDinwomenaffectedbyHFrEF.Impactoftestosteronedeciencyonclinicalstatus,morbidity,andmortalityoffemaleHFrEFTheevidenceofapositiveeffectplayedbytestosteroneoncardi

---

### Chunk 23/30
**Article:** EuropeanJournalofHeartFailure(2023)25,1891‚Äì1898POSITIONPAPERdoi:10.1002/ejhf.3036 (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.529

.............................................................................Inc,EliLilly,ImpulseDynamics,IntelliaTherapeutics,IonisPharmaceu-tical,JanssenResearch&DevelopmentLLC,Medscape/WebMDGlobalLLC,Merck,Novartis,NovoNordisk,ProscientoInc,QuidelCorpora-
tion,RadcliffeGroupLtd.,RecardioInc,ReCorMedical,RocheDiagnostics,Sano,SiemensHealthcareDiagnosticsandUs2.ai;andisaco-founderandnon-executivedirectorofUs2.ai.R.P.B.hasreceivedresearchsupportto
theUniversityofMichiganfromNovoNordiskandMedtronic,andconsult-ingfeesfromAstraZeneca,Bayer,Nevro,Roche,Procter&Gamble.M.M.hasreceivedhonorariafromCytokineticsandViforpharmaforpartici-
pationincommitteeforsponsoredclinicaltrialsandhasreceivedcon-sultinghonorariafromAbbott,AstraZeneca,Bayer,BoehringerIngelheim,RocheDiagnosticsinthelast3years.Allotherauthorshavenothing
todisclose.References1.McDonaghTA,MetraM,AdamoM,GardnerRS,BaumbachA,B√∂hmM,etal.;ESCScienticDocumentGroup.2021ESCGuidelinesforthediagnosisandtreatmentofacuteandchronicheartfailu

---

### Chunk 24/30
**Article:** Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update From the American Society of Echocardiography (2025)
**Journal:** Journal of the American Society of Echocardiography
**Section:** abstract | **Similarity:** 0.527

Updated guidelines for the evaluation of left ventricular diastolic function incorporating LAVI as a key parameter in the assessment algorithm. LAVI is an integral part of routine evaluation of patients with dyspnea or heart failure, providing powerful predictive marker of LV diastolic dysfunction.

---

### Chunk 25/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** results | **Similarity:** 0.526

diseasedurationandlowdensitylipoproteincholesterollevels.JAmCollCardiol
1996:28:573‚Äì579.50Pedersen&Saltin
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

CoakleyEH,RimmEB,ColditzG,KawachiI,WillettW.Predictorsofweightchangeinmen:resultsfrom
theHealthProfessionalsFollow-upStudy.IntJObesRelatMetabDisord1998:22:89‚Äì96.CoatsAJ,AdamopoulosS,MeyerTE,ConwayJ,SleightP.Effectsofphysicaltraininginchronicheartfailure.Lancet1990:335:63‚Äì66.CoatsAJ,AdamopoulosS,RadaelliA,McCanceA,MeyerTE,BernardiL,SoldaPL,DaveyP,OrmerodO,ForfarC.Controlledtrialofphysical
traininginchronicheartfailure.

---

### Chunk 26/30
**Article:** Hipertens√£o Arterial Sist√™mica II (2024)
**Journal:** Pos Graduacao MFI
**Section:** results | **Similarity:** 0.525

il√¢ncia aumentada nas mulheres.**
- Pr√©-menopausa: incid√™ncia de eventos cardiovasculares em mulheres √© muito menor (raz√µes 1:20 a 1:30 versus homens).
- P√≥s-menopausa: aproxima√ß√£o para quase 1:1, refletindo a perda do efeito protetor do estrog√™nio e a mudan√ßa no perfil de risco.
**Additional Key Findings**
- Limiares de exposi√ß√£o/oxida√ß√£o do LDL: acima de 0,8 h√° maior exposi√ß√£o do LDL √† oxida√ß√£o; alvo desej√°vel ‚â§0,7‚Äì0,8.
- Evid√™ncia hist√≥rica (Interarte, 2004) e revis√µes recentes (2023) sustentam a evolu√ß√£o do conhecimento sobre D, resist√™ncia √† insulina e risco cardiovascular.
- Lp(a) tem ~90% de variabilidade gen√©tica, indicando forte determina√ß√£o heredit√°ria e necessidade de estrat√©gias espec√≠ficas.
- Semaglutida em IC diast√≥lica e obesidade: estudo com n=529 mostrou redu√ß√£o de peso de 10% e apenas 1 evento de morte por IC no grupo tratado, sugerindo benef√≠cio cl√≠nico.

---

### Chunk 27/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.524

ss,orexcessivetirednesswhenrestingor
exercising,andwithobjectivesymptomsofreduced
systolicfunctionoftheleftventricleatrest.Asymptomaticleftventriculardysfunctionisoftentheprecursorofthissyndrome.Symptomsvaryfromverylightrestrictionoffunctiontoseriouslydis-
ablingsymptoms.Heartfailureisoftendividedinto
left-sided(themostfrequentandbestresearched
type)andright-sidedheartfailureandintoacute
(pulmonaryedema,cardiogenicshock)andchronic
heartfailure.Heartfailureisoftencausedby
ischemicdisease,butcanalsobecausedby,forexample,hypertensionorvalvularheartdisease(Braunwald&Libby,2008).Maximumoxygenuptake(VO2max)islowerinpatientswithheartfailure(Sullivanetal.,1989b;
Cohen-Solaletal.,1990;2001c).Thisiscaused,
amongotherthings,bythereducedpumpingfunc-
tionoftheheartandbyperipheralconditionsinthe
muscles(Massieetal.,1988;Sullivanetal.,1990;2001c).Acommonsymptomwithheartfailurepatientsismuscleatrophy,tiredness,andreduced
musclestrength(Wilsonetal.,1993;Ankeretal.,
1997;Harringtonetal.,1997).Heartfailu

---

### Chunk 28/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.523

olisA,McMurrayJ,PonikowskiP,RosenhekR,Ruschitzka
F,SavelievaI,SharmaS,SuwalskiP,
TamargoJL,TaylorCJ,vanGelderIC,VoorsAA,WindeckerS,ZamoranoJL,ZeppenfeldK.2016ESCguidelinesfor
themanagementofatrialbrillationde-velopedincollaborationwithEACTS.EurHeartJ.2016;37:2893‚Äì2962.2.YancyCW,JessupM,BozkurtB,ButlerJ,CaseyDEJr,DraznerMH,Fonarow
GC,GeraciSA,HorwichT,JanuzziJL,
JohnsonMR,KasperEK,LevyWC,MasoudiFA,McBrideP,McMurrayJ,MitchellJE,PetersonPN,RiegelB,Sam
F,StevensonLW,TangWH,TsaiEJ,
6A.M.Marraetal.ESCHeartFailure(2022)DOI:10.1002/ehf2.14117
	
	
Getulio Jos√© Mattos Do Amaral Filho - getfilho@yahoo.com.br - CPF: 034.983.039-88

WilkoffBL,AmericanCollegeofCardiol-ogyFoundation,AmericanHeartAssoci-ationTaskForceonPracticeGuidelines.2013ACCF/AHAguidelinefortheman-
agementofheartfailure:Areportof
theAmericanCollegeofCardiologyFoundation/AmericanHeartAssociationtaskforceonpracticeguidelines.JAmCollCardiol.2013;62:e147‚Äìe239.3.BealeAL,MeyerP,MarwickTH,

---

### Chunk 29/30
**Article:** Testosterone deficiency independently predicts mortality in women with HFrEF: insights from the T.O.S.CA. registry (2026)
**Journal:** Revista n√£o identificada
**Section:** discussion | **Similarity:** 0.520

derwenthospitaliza-tionduetocardiovascularreasonswhereas21cardiovascularhospitalizationswererecordedintheTDgroup(32%).AsdepictedinFigure1A,TDwasassociatedwithasignicantdifferenceintheoccurrenceoftheprimaryendpoint
(unadjustedHR:2.31,95%CI1.20‚Äì4.10,P=0.004).Further-more,TDwasalsoassociatedwithhigherall-causemortality(unadjustedHR:2.87,95%CI1.11‚Äì7.40,P=0.03)(FigureS1A)andcardiovascularhospitalization(unadjustedHR:2.37,95%CI1.20‚Äì7.40,P=0.01)(FigureS1B).MultivariableanalysisTable1showsthatTDresultedanindependentpredictorofthecombinedendpointofall-causemortality/cardiovascular
hospitalization(adjusted,adj-HR:10.45,95%CI3.54‚Äì17.01,P=0.001).Sameresultwasfoundconsideringtheindividualcomponentsofthecompositeendpoint(adj-HR:8.33,95%CI
5.36‚Äì15.11P=0.039forall-causemortality;adj-HR:2.41,95%CI1.13‚Äì4.50;P=0.02forcardiovascularhospitalization)(TableS1).Similarresultswereobtainedafterexcluding(n=8)patientswithLVEFbetween40and45%(Table2).DiscussionThemainndingsofthecurrentstudyarethat(1)

---

### Chunk 30/30
**Article:** Exercise as medicine ‚Äì evidence for prescribing exercise as therapy in 26 different chronic diseases (2026)
**Journal:** Revista n√£o identificada
**Section:** other | **Similarity:** 0.520

SendonJL,NieminenMS,
PierardL,RemmeWJ.Guidelines
forthediagnosisandtreatmentofchronicheartfailure:executivesummary(update2005):theTask
ForcefortheDiagnosisand
TreatmentofChronicHeartFailureoftheEuropeanSocietyofCardiology.EurHeartJ2005:26:
1115‚Äì1140.TakenakaK,SakamotoT,AmanoK,OkuJ,FujinamiK,MurakamiT,TodaI,KawakuboK,SugimotoT.

---

